Entering text into the input field will update the search result below

Achaogen to host lunch updating investors on commercial strategy post FDA approval of Plazomicin

Jul. 11, 2018 7:39 AM ETAchaogen, Inc. (AKAOQ) StockBy: Gaurav Batavia, SA News Editor10 Comments
  • Achaogen (NASDAQ:AKAO) will host a lunch updating investors on the market opportunities for plazomicin, including the treatment of serious bacterial infections due to MDR Enterobacteriaceae with perspectives from key opinion leaders Steven Burdette, M.D. and Joshua Rosenberg, M.D., on Thursday, July 12, from 12:00pm – 1:30pm ET in New York City.
  • The management will present an update on the commercial strategy for ZEMDRI (plazomicin), which recently received U.S. Food and Drug Administration (FDA) approval for treating adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options.
  • Shares -2.93%.
  • Press Release

Recommended For You

Related Stocks

SymbolLast Price% Chg
AKAOQ--
Achaogen, Inc.